154 related articles for article (PubMed ID: 37341499)
1. Differential Effects of Glutamine Inhibition Strategies on Antitumor CD8 T Cells.
Madden MZ; Ye X; Chi C; Fisher EL; Wolf MM; Needle GA; Bader JE; Patterson AR; Reinfeld BI; Landis MD; Hathaway ES; Muka JE; O'Neil RT; Karijolich J; Philip M; Rathmell JC
J Immunol; 2023 Aug; 211(4):563-575. PubMed ID: 37341499
[TBL] [Abstract][Full Text] [Related]
2. Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug.
Rais R; Lemberg KM; Tenora L; Arwood ML; Pal A; Alt J; Wu Y; Lam J; Aguilar JMH; Zhao L; Peters DE; Tallon C; Pandey R; Thomas AG; Dash RP; Seiwert T; Majer P; Leone RD; Powell JD; Slusher BS
Sci Adv; 2022 Nov; 8(46):eabq5925. PubMed ID: 36383674
[TBL] [Abstract][Full Text] [Related]
3. The inhibition by 6-diazo-5-oxo-l-norleucine of glutamine catabolism of the cultured human lymphoblast.
Willis RC; Seegmiller JE
J Cell Physiol; 1977 Dec; 93(3):375-82. PubMed ID: 22551
[TBL] [Abstract][Full Text] [Related]
4. Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine.
Wang SZ; Poore B; Alt J; Price A; Allen SJ; Hanaford AR; Kaur H; Orr BA; Slusher BS; Eberhart CG; Raabe EH; Rubens JA
Clin Cancer Res; 2019 Oct; 25(19):5925-5936. PubMed ID: 31300448
[TBL] [Abstract][Full Text] [Related]
5. Protective Effects of Glutamine Antagonist 6-Diazo-5-Oxo-l-Norleucine in Mice with Alphavirus Encephalomyelitis.
Manivannan S; Baxter VK; Schultz KL; Slusher BS; Griffin DE
J Virol; 2016 Oct; 90(20):9251-62. PubMed ID: 27489275
[TBL] [Abstract][Full Text] [Related]
6. Targeting glutamine metabolism rescues mice from late-stage cerebral malaria.
Gordon EB; Hart GT; Tran TM; Waisberg M; Akkaya M; Kim AS; Hamilton SE; Pena M; Yazew T; Qi CF; Lee CF; Lo YC; Miller LH; Powell JD; Pierce SK
Proc Natl Acad Sci U S A; 2015 Oct; 112(42):13075-80. PubMed ID: 26438846
[TBL] [Abstract][Full Text] [Related]
7. Additive effects of inhibiting both mTOR and glutamine metabolism on the arthritis in SKG mice.
Ueda Y; Saegusa J; Okano T; Sendo S; Yamada H; Nishimura K; Morinobu A
Sci Rep; 2019 Apr; 9(1):6374. PubMed ID: 31011190
[TBL] [Abstract][Full Text] [Related]
8. Reinforce the antitumor activity of CD8
Nabe S; Yamada T; Suzuki J; Toriyama K; Yasuoka T; Kuwahara M; Shiraishi A; Takenaka K; Yasukawa M; Yamashita M
Cancer Sci; 2018 Dec; 109(12):3737-3750. PubMed ID: 30302856
[TBL] [Abstract][Full Text] [Related]
9. Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy.
Sharma NS; Gupta VK; Garrido VT; Hadad R; Durden BC; Kesh K; Giri B; Ferrantella A; Dudeja V; Saluja A; Banerjee S
J Clin Invest; 2020 Jan; 130(1):451-465. PubMed ID: 31613799
[TBL] [Abstract][Full Text] [Related]
10. Preventing Allograft Rejection by Targeting Immune Metabolism.
Lee CF; Lo YC; Cheng CH; Furtmüller GJ; Oh B; Andrade-Oliveira V; Thomas AG; Bowman CE; Slusher BS; Wolfgang MJ; Brandacher G; Powell JD
Cell Rep; 2015 Oct; 13(4):760-770. PubMed ID: 26489460
[TBL] [Abstract][Full Text] [Related]
11. DON of Hope: Starving Pancreatic Cancer by Glutamine Antagonism.
Pillai R; Papagiannakopoulous T
Cancer Res; 2024 Feb; 84(3):349-350. PubMed ID: 38117482
[TBL] [Abstract][Full Text] [Related]
12. Influence of 6-diazo-5-oxo-L-norleucine (DON), a glutamine analogue, on cartilaginous differentiation in mouse limb buds in vitro.
Aydelotte MB; Kochhar DM
Differentiation; 1975 Oct; 4(2):73-80. PubMed ID: 1183764
[TBL] [Abstract][Full Text] [Related]
13. We're Not "DON" Yet: Optimal Dosing and Prodrug Delivery of
Lemberg KM; Vornov JJ; Rais R; Slusher BS
Mol Cancer Ther; 2018 Sep; 17(9):1824-1832. PubMed ID: 30181331
[TBL] [Abstract][Full Text] [Related]
14. Metabolic reprogramming by ex vivo glutamine inhibition endows CAR-T cells with less-differentiated phenotype and persistent antitumor activity.
Shen L; Xiao Y; Zhang C; Li S; Teng X; Cui L; Liu T; Wu N; Lu Z
Cancer Lett; 2022 Jul; 538():215710. PubMed ID: 35489446
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of glutamine metabolism accelerates resolution of acute lung injury.
Vigeland CL; Beggs HS; Collins SL; Chan-Li Y; Powell JD; Doerschuk CM; Horton MR
Physiol Rep; 2019 Mar; 7(5):e14019. PubMed ID: 30821123
[TBL] [Abstract][Full Text] [Related]
16. Targeting Glutamine Metabolism Ameliorates Autoimmune Hepatitis
Yu Q; Tu H; Yin X; Peng C; Dou C; Yang W; Wu W; Guan X; Li J; Yan H; Zang Y; Jiang H; Xia Q
Front Immunol; 2022; 13():880262. PubMed ID: 35663990
[TBL] [Abstract][Full Text] [Related]
17. Targeting glutamine metabolism as an effective means to promote allograft acceptance while inhibit tumor growth.
Lee CF; Cheng CH; Hung HC; Chan KM; Lee WC
Transpl Immunol; 2020 Dec; 63():101336. PubMed ID: 32937197
[TBL] [Abstract][Full Text] [Related]
18. Antagonizing Bcl-2 family members sensitizes neuroblastoma and Ewing's sarcoma to an inhibitor of glutamine metabolism.
Olsen RR; Mary-Sinclair MN; Yin Z; Freeman KW
PLoS One; 2015; 10(1):e0116998. PubMed ID: 25615615
[TBL] [Abstract][Full Text] [Related]
19. Modulation of heparan sulfate biosynthesis. Effects of 6-diazo-5-oxo-L-norleucine and low glutamine on the synthesis of heparan sulfate proteoglycan by human colon carcinoma cells.
Iozzo RV; Clark CC
J Biol Chem; 1987 Aug; 262(23):11188-99. PubMed ID: 2956263
[TBL] [Abstract][Full Text] [Related]
20. A redox-responsive prodrug for tumor-targeted glutamine restriction.
Prange CJ; Sayed NYB; Feng B; Goepfert C; Trujillo DO; Hu X; Tang L
J Control Release; 2024 Apr; 368():251-264. PubMed ID: 38403173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
